Company profile for NantKwest

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NantKwest is an innovative clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. NantKwest is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to ...
NantKwest is an innovative clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. NantKwest is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. The NantKwest “off-the-shelf” activated Natural Killer (NK) platform is designed to destroy cancer and virally infected cells from the body.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
9920 Jefferson Blvd. Culver City, CA 90232
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20210308005285/en/ImmunityBio-and-NantKwest-Begin-Dosing-Participants-in-Global-Trials-for-Novel-COVID-19-Vaccine-Subcutaneous-Route-in-South-Africa-Oral-and-Sublingual-in-the-U.S.

BUSINESSWIRE
08 Mar 2021

https://www.businesswire.com/news/home/20210211005960/en/ImmunityBio-and-NantKwest-Announce-FDA-Authorization-to-Study-hAd5-T-Cell-COVID-19-Vaccine-for-Combination-of-Subcutaneous-Oral-and-Sublingual-Boost-to-Induce-T-Cell-Mucosal-and-Antibody-Immunity

BUSINESSWIRE
11 Feb 2021

https://nantkwest.com/nantkwest-immunitybio-announce-positive-interim-data-on-survival-rates-in-metastatic-pancreatic-cancer-trials/

PRESS RELEASE
13 Jan 2021

https://www.businesswire.com/news/home/20201222005352/en

BUSINESSWIRE
22 Dec 2020

https://www.businesswire.com/news/home/20201222005352/en/CytRx-Comments-on-Proposed-Combination-of-ImmunityBio-and-NantKwest

BUSINESSWIRE
22 Dec 2020

https://www.businesswire.com/news/home/20201222005352/en

BUSINESSWIRE
22 Dec 2020

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty